Q3 2024 IQVIA Holdings Inc Earnings Call
[inaudible]
Speaker Change: Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the IQ via 3rd Quarter 2024, Ernings Conference Call.
Speaker Change: All lines have been placed on mute to prevent any background noise. After the speaker is remarks, there will be a question in answer session. If you would like to ask a question during this time, simply press star, follow with a number on your telephone keypad.
Speaker Change: If you would like to withdraw your question.
Speaker Change: Press the pound key as a reminder this call is being reported. Thank you. I would like to turn the call over to Kerri Joseph's senior vice president, Investor Relations and Treasury. The Surge Joseph, please begin your conference.
Speaker Change: Thank you all for your attention.
Kerri Joseph: Good morning everyone. Thank you for joining out third quarter 2020 for earnings call.
Speaker Change: With me today, Ari Bousbib, Kerriman and Chief Executive Officer, Rob Bruehlman, Executive Vice President, Chief Financial Officer, Eric Sherbert, Executive Vice President and General Counsel, Mike Fiedock, Senior Vice President, Financial Planning and Analysis.
Kerri Joseph: and Constable Paroney, Senior Director and Vester Relations.
Kerri Joseph: Today we will be referencing a presentation that will be visible during this call for those of you on our webcast. This presentation will also be available following this call in the events and presentation section of our review of investor relations website at IR.Ikevia.com.
Kerri Joseph: Before we begin, I'd like to caution listeners that certain information discussed by management during this conference call went through forward-looking statements.
Kerri Joseph: After all, results could differ materially from those states that are implied by foreign-looking state and is due to risk and are certain to associate with the company's business, which are discussed in the company's filings with the securities and exchange commission, including a annual report of Form 10K.
Kerri Joseph: and subsequent SEC Firewins.
Kerri Joseph: In addition, we will discuss certain non-gap financial measures on this call, which should be considered a supplement to and not substitute for financial measures prepared in accordance with gap.
Kerri Joseph: A reconciliation of these non-gap measures to the comparable gap measures is included in the press release and conference call presentation.
Speaker Change: I would now like to turn a call over to our chairman and CEO Ari Bousbib.
Ari Bousbib: Thank you, Kerri and we want to get everyone. Thank you for joining us today to discuss our third quarter results.
Ari Bousbib: I QV had delivered another quarter of strong operational results, revenue came in above the high end of our guidance range, representing about six and a half percent growth, excluding the impact of foreign exchange and COVID-related work.
Ari Bousbib: And we also delivered 14% growth in adjusted diluted EPS.
Ari Bousbib: As we expect the environment for our short cycle businesses continues to improve.
Ari Bousbib: As our clients are launching new drugs and executing on critical commercial programs.
Ari Bousbib: In fact, Tas revenue growth accelerated in Q3 to over 8% year over year, with growth in all sub-segment.
Ari Bousbib: This reaffirmed the second half growth trajectory that we had anticipated for Taz since the beginning of the year.
Ari Bousbib: And we now expect us to grow for the year at the high end of our mid-single digit range.
Ari Bousbib: On the critical side, the near-term market environment continues to be chopped years we've been discussing in prior earnings calls.
Ari Bousbib: None of this is new, but as you know, we've been facing aggressive competitive pricing and tougher negotiations.
Ari Bousbib: Additionally, the trend that started over a year and a half ago with large farmer reprioritized the program portfolios as a result of the IRA has been continuing.
Ari Bousbib: and this has been leading to a higher than normal level of cancellations.
Ari Bousbib: And we expect this to be the case again in the fourth quarter.
Ari Bousbib: On the EDP side, funding levels this year have improved, but as you know, it does take time for this funding to translate into actual RSP flows and even more time to translate into awards.
Ari Bousbib: are bookings in the quarter included a substantial cancellation due to drug utility.
Ari Bousbib: That impacted a quarterly net new business by approximately $350 million.
Ari Bousbib: For that's one trial.
Ari Bousbib: The report with net book to be was 1.06, but excluding this specific cancellation, the book to be with the 1.22. Lastly, in late September.
Ari Bousbib: Two clients notified us of their need to delay two mega studies that were already in start-up phase.
Ari Bousbib: Due to client-related logistics issues.
Ari Bousbib: This affects our short term guidance and one will share more about that later.
Ari Bousbib: Why will you not be dead?
Ari Bousbib: Through these short-term challenges, it's important to remember that our Seattle business is a long cycle business.
Ari Bousbib: The demand metrics give us confidence in the strike and with a billion sub-off business.
Ari Bousbib: I'd like to share some details of what we are seeing.
Ari Bousbib: First Me.
Ari Bousbib: As you may know, many large former companies have been running processes this year to reevaluate and consolidate their strategic partnerships.
Ari Bousbib: Today!
Ari Bousbib: We have successfully renewed every single large pharmaceutical strategic partnership.
Ari Bousbib: In fact.
Ari Bousbib: With added new relationships, displaced incumbents, and expanded the scope in over half a dozen of our strategic partnerships with large farmer clients.
Ari Bousbib: There are two aspects to this successful performance by the RDS team.
Ari Bousbib: One,
Ari Bousbib: is that our existing large pharmaceuticals have reaffirmed their trust in IQVIA.
Ari Bousbib: and two, it opens up opportunities for us to gain great or share of wallet in future programs because these clients have consolidated their strategic partnerships.
Ari Bousbib: in the NET World.
Ari Bousbib: Biotech funding reached about $16 billion in the quarter according to BioWorld. And that means that you're today's.
Ari Bousbib: Biotech funding was over $80 billion which represents more than 50% growth in funding year-over-year.
Ari Bousbib: Now again.
Ari Bousbib: As I remarked earlier, it does take time and it could take a year or half before that funding translates in actual awards.
Speaker Change: 3. Our backlog reached a new record of $31.1 billion at the end of the quarter, and that represents growth of 8% compared to the prior year.
Speaker Change: 4. Our Frailing 12 Month Book to Be a Remains Healthy at 1.22.
Speaker Change: Feast observation, our next 12 month revenue from backlog is up to 5.5% year over year.
Speaker Change: A quarterly RFP flow continued the same trend we saw in the first half, increasing mid-singredigits year over year.
Speaker Change: and finally a qualified pipeline in the quarter is up across all customer segments and it's grew low double digits overall compared to the prior year.
Speaker Change: and that is good. Now just to be balanced I should point out that in stronger market environments that qualified pipelines are sometimes been up in high double digits.
Speaker Change: Now, let's turn to the results of the court.
Speaker Change: Revenue for the quarter due 4.3% on a reported basis.
Speaker Change: and 4.2% at Constant Currency.
Speaker Change: Compared to last year, an excluding COVID related work from both periods, with gluder topline about 6.5% at constant currency, of which just under 5% is organic growth.
Speaker Change: 3rd quarter adjusted EBD's increased 5.7% driven by revenue growth and ongoing cost management discipline, and that resulted in 30 bits of margin expansion.
Speaker Change: Third quarter adjusted diluted EPS of $2.84 increased 14.1% year over year.
Speaker Change: I'd like to share a few highlights.
Speaker Change: As is our practice of business activity.
Speaker Change: Let me start with Ari and the Earth.
Speaker Change: Well, we continue to differentiate without therapeutic expertise.
Speaker Change: Clinical Technology and Public Health offerings.
Speaker Change: I give you a one a top ten form of partnership as a new preferred provider for Central Lab, as well as secured extension for several existing FSB engagements.
Speaker Change: In clinical monitoring, data management and clinical technology.
Speaker Change: We were awarded a strategic partnership to provide this city solutions.
Speaker Change: For a Metabolic and Caljuvasti Program at the top 15 Pharmacline, with the only company that can offer this visit, services, and technology without having to partner with third parties.
Speaker Change: with Inoncology.
Speaker Change: And which is as we know, a teacher of the care and our foreign industry, were selected by several leading sponsors in the core, including.
Speaker Change: A US biotech client to manage a large global phase 3 study for Reynolds cell cost in number for patients who are progressed after first-line immunotherapy combinations.
Speaker Change: The last form of customer to conduct an early phase trial in prostate cancer, leveraging our expertise in dose escalation and dose expansion study designs.
Speaker Change: and BioTech Lion to run a global phase 3 study for a bio-similar, targeting multiple mic, mageloma.
Speaker Change: This project aims to bring the first biocimilar for multiple myeloma to market.
Speaker Change: Ebalo Cecliant, leader in Selenge in Therapy.
Speaker Change: to conduct a groundbreaking phase ritual for reoccurring cancer in the lymphatic system.
Speaker Change: Across these awards, we differentiate with our ability to run global studies with dedicated teams, as well as our AI-enabled site selection solution.
Speaker Change: Within clinical technology, in fact, we continue to expand our recently launched one home for sites offering.
Speaker Change: A biotech client selected a QVAT to increase clinical trial capacity by stringlining access to multiple vendor sites via our single sign-on platform.
Speaker Change: In the call, a large-vailurate client selected a Kyuvian to expedite the setup of a trial to deliver vaccines for the MPOX in sub-Saharan Africa addressing a critical outbreak in the region.
Speaker Change: and Significant Unmet Medico Needs.
Speaker Change: Finally, I give you an partnership with the Coalition for Epidemic Preparedness and Innovations. SEPY.
Speaker Change: The Rwanda Ungovernment and the Sabine Institute.
Speaker Change: Responded to an outbreak of the Marburg virus.
Speaker Change: The hemorrhagic fever with greater than 50% fatality in wonder at the end of September.
Speaker Change: Our organizations collaborated to mobilize and dose the first patients with an investigation or vaccination within nine days of the outbreak.
Speaker Change: Moving to Taz, as you so come on results, the business is recovering even better than we have for custard.
Speaker Change: One area we continue to make great strides in is in building differentiating AI capabilities across our offerings.
Speaker Change: You will have seen we recently launched the Ayyubia AI Assistant, which is a new Generative AI tool designed to provide live science customers with quick and powerful insights through a user-friendly conversation or interface.
Speaker Change: This allows users to ask complex business questions and receive comprehensive and reliable answers in real time.
Speaker Change: A QVA AI Assistant is built on a QVA StraitMic healthcare grade AI which enables extensive privacy safeguards and provides expert validation of accurate reliable outputs.
Speaker Change: As is demanded by the healthcare industry.
Speaker Change: IQVL was awarded a multi-year contract by a large format client to deliver our next best action offering for sales reps across nine countries.
Speaker Change: This AI-enabled solution optimizes sales rate and engagement activities and enhances their interactions with HCPs.
Speaker Change: I give you a secure, multi-year contract with an author American biotech client to improve work through efficiency to an integrated fully connected intelligence solution that includes OCE, orchestrated analytics and one key offerings.
Speaker Change: The top 10 clients shows a QVR to improve HP and Gazements for a new skis of Frenia treatment.
Speaker Change: and in this case, we displaced the incumbent by offering a solution that will enable daily alerts based on near real-time inputs versus the incumbents weekly frequency.
Speaker Change: The top five former clients awarded a QVA in multi-year contract.
Speaker Change: To provide corporate support for oncology and women's health franchise. These dealing handsets patient access to medications and drives better health outcomes.
Speaker Change: A couple of examples in the real world segment, a top 5 farm-acline selected like UVA to support the launch of a new GLP-1 asset targeting weight loss based on European
The top five former clients and is accused of providing the evidence based approach for a client's medical affairs team to optimize funding decisions and pre-long activities in the North American market.
A top 20 last former client awarded a QDO contract to support engagements with ACPs and TLLs.
Speaker Change: based on detailed share of voice analysis of scientific and clinical experts in nine countries across all cultural-appuetic areas for the plant.
Speaker Change: Finally, and before I turn it over to Ron for more details on our financial performance.
Speaker Change: I'd like to invite you.
Speaker Change: to our Iqqia Invested Day, which has been scheduled for December 10th.
on the campus of our headquarters in Durum, North Carolina.
Speaker Change: Our Investor Relations team will be available to provide additional logistical details. Event information is already available on our Investor Portal.
Ross, thanks Ari and good morning everyone. Let's start by reviewing Revenue.
3,896 million dollars grew 4.3% on a reported basis and 4.2% of constant currency.
Speaker Change: In the quarter, COVID-19-related revenues were approximately $20 million, down from about $100 million in the third quarter of 2023.
Now, excluding all COVID-related work from both this year and last, constant currenty growth was about 6.5% of which just under 5% with organic.
The majority of the acquisition contribution was in the TAD segment as is typical.
Technology and Analytics Solutions revenue was $154 million, up $8.6% reported in 8.2% of constant current system.
R&D Solutions revenue of $2,162 million was up 1.9% recorded and an even 2% constant currency.
Excluding all COVID-19 were part of the constant currency in R&DF was about 6%.
Speaker Change: Lastly, contract sales and medical solutions are CFMF, revenue of $180 million to coin 1.6% reported and 1.1% of constant currency.
Speaker Change: Year to date revenue was $11 billion, $447 billion up, 3% on a reported basis in 3.5% constant currency.
Speaker Change: Scrooting all COVID-related work wrote the constant currency with 6% year to date.
Technology and Analytics Solutions Revenue was $4,522 million dollars a year today, up 3.9% reported, and 4.3% constant currency.
Speaker Change: including all COVID-related work, growth at constant currency in TAS was 5%. Now, as a reminder, a Q1223 was the last quarter where TAS revenue had a meaningful contribution from COVID-related work.
R&D Solutions here today grab a new of $6,44 million with up 2.6% at actual FX rates and 3% at constant currency, excluding all COVID-related work growth at constant currency and R&DF with 7%.
Lastly, contract sales and medical solutions year to date revenue of $541 million was flat on a reported basis, not 3% consequences.
moved down to P&L, adjusted to EVIT dollars, $939 million for the third quarter, which was growth, a 5.7 percent, while year to date adjusted EVIT dollars was $2 billion, $688 million, up to 3.3 percent year every year.
Third quarter gap in income was $285 million in gap the Litter's earnings per share was $1.55.
Speaker Change: In her today, Gat Netan comes with $936 million which represents $5.8% of the Luda earnings per share.
Speaker Change: adjusted net income was $523 million for the third quarter. Adjusted the loot at earnings per share was $2.84. Up 13.2% and 14.1% respectively versus prior year.
Here today to Justin Netting come with $1,478,000 or $8.26 for share.
Speaker Change: A backall against September 30th was $31.1 billion. That's up 8% year over year and 6.7% of consequences.
Next 12 months revenue from backlog with $7.8 billion, growing $5.5 per cent year every year.
We're doing the balance sheet now as of September 30, cash and cash at Bliblins total $1 billion, $572 million in gross debt with $13 billion, $512 million.
and not resulted in a net debt of 11 billion, 940 million dollars. Our net leverage ratio at the end of the quarter was 3.27 times, treeling 12 months of justice EBITDA.
Third quarter cash flow from operations with 720 million, 21 million dollars and capital expenditures were 150 million dollars resulting in very strong free cash flow at 571 million dollars.
He saw in the court that we repurchased $200 million of our shares. That leaves us just under $2.2 billion of their share repurchased authorization for Manning under the current program.
Okay, let's turn the buttons now.
Speaker Change: Now, while our views on industry fundamentals remain positive, we're updating our full-year guidance student at the delay.
in the two separate fast burning mega-twiles, which clients communicated to us at the end of the quarter. These delays resulted from client-related logistical issues.
Our team is working closely with these customers to ensure timely resumption of the trials in 2025.
Speaker Change: For the year we now expect revenue between $15 billion, $350 million and $15 billion, $400 million. Adjusted EBITDA to be between $3,675 million and $3,700 million.
and adjusted the blue that earnings per share to be between $11.10 and $11.20.
There's no material change from a prior guidance to our assumptions around COVID-related step-down and foreign exchange.
Speaker Change: The revenue growth contributions from acquisitions is expected to be about a point in the half for the year.
Now, the second that sees me at the segment level, we currently expect TAS to grow approximately 6% for the full year and R&DF's approximately 5%. Both growth rates are at constant currency excluding the impact of the COVID revenue step down.
Speaker Change: For the fourth quarter, we've stuck revenue to leave between $3,903 million dollars.
and $3,950,000,000. This includes Taz Revenue of...
Growth of approximately 8% in R&DF's revenue growth of about 1%. Both at constant currency and in the case of R&DF excluding COVID-related impacts.
A just of the Eva does expected between $987 million and $1 billion, $12 million. In a just-deleted EPS, for the quarter, it's expected to be between $3.8 since $3.8.
and this guidance assumes that foreign currency rates as of October 30 continue for the bounce of the year.
said if summarize, we delivered another quarter of strong operational results.
Revenue came in above the high end of our guidance at about six and a half percent year over year excluding the impact of foreign exchange and COVID related work.
Speaker Change: Joseph Eba, John Morgan, expanded to 24.1%, adjusted to the root of EPS group by 14% as intersex and spent with no longer a headwind.
Free cascades with against wrong going 31% year over year representing 109% cash conversion of a just in that income.
RDS bookings were affected by the cancellation of one large program due to drug fidelity.
We updated our Q4 guidance to reflect the delayed start of two fast burning mega trials that are now expected to resume again in 2025.
And while we are experiencing some near-term bumpiness in R&DFs, forward-looking indicators continue to signal the healthy demand environment, confirming the strength and resilience of this business into 2025 and beyond.
And with that, let me hand it back over to the operator that opened the Q&A session.
At this time, I would like to remind everyone in order to ask a question, press R, then the number one in your telephone keypad. We request that you please limit yourself to just one question, so that others in the queue may participate as well. We'll pause for a moment to compile the Q&A
Your first question comes from the line of end, Gmizuhu, your line is open.
and thank you so much.
Any thoughts on preliminary 2025? I know the industry's going through a kept time now, but do you think you could still grow in that kind of high single digit range given the backdrop? Thanks.
Well, thanks, you and, you know, we don't usually give guidance for the following year at the time of the third quarter earnings release.
But we do plan to at least give some indication of what 25 we look like at our investor, meaning on December 10. And as always,
to give you more precise guidance for the year concurrent with the four year earnings release.
Speaker Change: Now having said that.
Speaker Change: Um, Loki.
And then, I'm gonna be proud from everybody that's in the room, just telling you to do it and I'm on the tell you that.
Speaker Change: and Alduda, because the environment is so shaky and obviously you're wondering what's going to happen 25. So look, if you look at 24, we do.
We will have grown the company about missing the digits.
Speaker Change: OK, after all the short-term challenges that we signal are absorbed.
Speaker Change: and my expectation is that it'll be similar in 25.
Speaker Change: That's really a high level expectation. We have a finished star planning process as you can imagine.
But if you look at the segment's style,
has predicted rebounded in the second half and does it's a short cycle of business. I think things are coming back.
As expected, and we anticipate this will continue. So if it doesn't grow this year, a concept currency again around 6% or so, then I think I'm expecting that the same will be true at least in 25.
Speaker Change: and then for all the S which will continue to.
Speaker Change: Deal with these short-term cancellations.
in Q4 and probably the only part of 25. We are projecting a 5-ish percent growth, 5 percent plus growth.
Speaker Change: For all the years, I'm going to assume this early stage at a little bit similar. And that's what's guiding my...
Observation, I think company wide will be around those levels as well in 25.
That's just as a placeholder.
Speaker Change: I invite you to join us on December 10 where our planning will be more advanced and we will share more about that and certainly a full year of the 10 guidance when we release career earnings. Thank you, Aaron.
Speaker Change: Thank you.
Your next question comes from the line of slow-mo with faithful. Your line is open.
Hi, thank you very much.
Speaker Change: Ari, I knew it's one question, but I just want to get a lot more detail if you can on the trial delays
I can't talk about two trial issues also. They were talking about financial reprioratization and stuff like that with some of their clients.
You're talking about some kind of logistical issues. Can you give us a little bit more detail? Are these logistics, you know, physical logistics, you know, what else?
would be involved in that, and said, have anything to do with the financials? And what kind of confidence do you have to come projects? We're really ramped into the second half of 25. And you know, if you can kind of flesh that out as much as possible to appreciate it. Yeah. So look, I mean, what's all going to convince an experiencing is absolutely coincidental. That's too sharp, all that. And we are too trial. I understand why you're asking the question.
Speaker Change: Just again, step back and look at what's happening. We've got the general environment where...
Speaker Change: As I stated in my introductory remarks, Raj Phama has been repatrioritizing their programs, and nothing new here, and that has led the direct consequence of the IRA.
Speaker Change: That has led to an elevated number of cancellations. That affects the industry, that's the market environment.
Speaker Change: and frankly, even in that environment we normally should be expected given our scale and performance and momentum.
Speaker Change: We should be expected to continue to deliver and that should be for the first three quarters of the year.
Speaker Change: Separately and unfortunately.
At the same time we have had to build with a very large cancellation that has nothing to do with re-portisation as to do with subtlety.
Speaker Change: and that obviously affecting our short term. Now in a normal environment, we're able to absorb that and move on.
But because it's such a tough environment and we're dealing with a general, heightened level of clansylations, we've not been able to absorb that.
Again, separately, an unfortunately, concluidly.
Two clients, this is totally independent of anyone else, of any reproutization, of any financial considerations, of anything else.
Have had, for their own reasons, we know what the reasons are, I cannot share them with you. We will subject to the district and the district for all of the district reasons.
It has absolutely nothing to do with the drug with us, with financial.
We just can't tell you where the reasons are, I regret that, but those trials will resume, they happen to be fast burning and they have to be very large.
We have confidence that they will resume in 25.
Now, I know it's a lot to absorb and when you look at the whole picture, that's, you know, all the different things.
Speaker Change: and I regretting as much as you, but that's the reality we're facing with.
Speaker Change: A choppy environment will navigate that on the normal circumstances, but we've had to deal with two discrete events.
and related really to the environment.
Speaker Change: and thank you for all the help.
Speaker Change: Yep.
Thank you.
Speaker Change: Your next question comes from the line of Anne with JP Morgan. Your line is open.
Hi guys, thanks so much for the question. I was hoping perhaps you could help us understand just maybe the timing.
of some of these dynamics of the cancellation. You know, how much notice you get in advance. And...
When we think about the delays for pushing to the back half of next year, today impact any other projects for 2025 or does that become incremental to 2025? Thanks very much.
OK, on cancellations typically look at depends, all these kinds of cancellations and I'm going to roughly say...
that in this past year, what we are seeing is that about half.
He's due to the repurchase and about half is the normal drug security based on results.
How does it happen? Were the reprisorization, you know, it's a process that our clients are going through?
Speaker Change: and um...
You know, they've been going through this for a year and a half.
and I believe we are picking at this point.
It has an end, this process has an end. I see this ending at the end of this year. That's my prediction, it's one my prediction. But I think that we're going to steal C.
Elevated cancellations in the fourth quarter.
We don't, now I think that's not good.
A number of squad clients in the world have set before.
In normally it's about a half a billion dollars and it can vary plus or minus two hundred million dollars either side. By definition it's not a constant number. It cannot be the same number every quarter.
Okay, so they are called as what it's 300, they are called as 250, they are called as what it's 607,000.
The average is around 500.
and I think that we are saying, I will be misunderstood. We see corals where we have double that number.
because of these reprioritizations. Okay? So that's what we're dealing with.
Speaker Change: The traditional cancellations, other than re-portizations, the traditional cancellations that are due to data is usually takes time because you've got a piece of data that's not favorable as you know, there are independent channels.
Investigative panelists are reviewed at data discussions with the FDA. It's a long process.
and even, you know, in order to reach the decision to cancel, it takes time. When that happens, it also takes time to unwind the trial. If the trial is ongoing,
As opposed to the trials that are cancelled because of reproiratization, which are things that are simply taken out of the backlog.
Programmed by a cancelled because they are in the middle in flight because of results, it takes time to unwind, it could take two or three quarters.
because we have to deal with patients that have been closed, that are on the treatment etc. So there are serious reasons and often it leads to additional bookings of extra work.
In order to facilitate that disengagement.
Speaker Change: So that's again, it's a complex on a winding process but I hope that helps answer your question. And you also I think asked about delays and whether the delays at incremental work in 2025.
Don't forget, these are multi-year trials. So if 24 work gets pushed into 25, sure we can take it up there, but 25 work gets pushed into 26.
So I wouldn't think of these as being incremental to 2025. That's correct. However, the sequential growth will be affected.
So, you know, just because of the comparison. Exactly. And we'll give you more information on this sequential growth that we expect as we go forward during our, you know, normal guidance process.
Great, thank you very much.
Speaker Change: [inaudible]
Here next question comes from the line of Luke at Barclays, your line is open.
Hey guys, thanks. A couple of clamps here start on the M&A. You guys did 428 million I think in the quarter. Any update there on like the financial profile and is all this in tabs. And kind of how we think about that that building is growing so we can for modeling perspective in the next year.
Thank you. Well, you're correct. As you have been typically the case, the majority of our acquisition contribution is in task, but I would point out that in the quarter, cars had very strong step up in already growth.
In fact, more than three times sequentially, the company wide organic growth was just under 5%.
Exceeding Lock positions.
and so what we're doing is we're going to be doing just over one and a half points to our about six and a half points of growth at constant currency exclusion curvy.
Now, if you do the math, you'll see that the organic growth in Taz was also made single digits, which again is over three times what it was in the prior court. So strong in Taz across the board organically.
You know, since you asked about acquisitions, I just want to step back and reiterate what I've said many times before, and that is that acquisitions are only important parts.
Speaker Change: of our growth algorithm.
Always has been the case and hopefully we will continue to be the case. In fact, we always end at, you know, at least.
Speaker Change: 2 points of incremental growth for my positions, but if you look at our number, you'll see that historically we've never been able to do 2 points plus a row. It's been more between 1 and 1 and 1 and 1 and 1 and 1 and 1 and 1 and 1 and 1 and 1 and 2 is a whole lot more.
of Constitution for my positions. Now, very mind we do a very large number of tiny, tiny deals. You have the list from the view just given example, a couple of examples this year and the
In the Tads area, we did an acquisition of a commercial engagement company H3O that has a million dollars of annual revenue.
We did a real world platform B2I that had slightly over a million dollars of revenue. So when you look at the total number of acquisitions, we do it. Looks like a really big number.
Speaker Change: but there are any number, very small actors. That's difficult. If you look at our list of actual acquisitions, you know, with all these little fancy names and they are important. Okay, these are little deals that we, with this because we believe we are pretty good at buying companies.
Speaker Change: With potential growth and typically after we integrate them with, you know, urine or two of ownership, they do very well. So, again, the vast majority of these did have a very little revenue. Now.
Sometimes we have to pay up a lot. There are, there's a handful of refugees we've done in the past, in the recent times, that we've paid 10 times revenue for.
Speaker Change: You know I'm thinking of the DMD for example, my couple of years which facilitated our entry into the digital states. We think almost ten times the revenue for that company. So if you will be acquisition number.
The daughter paid for the acquisitions and the revenue costreviewers are not connected.
For example, you're today, what's the spend on acquisition zero to date? As a Q3, 600 for a van. Okay, we spend $604 million year to date on acquisitions at the end of the third quarter.
Speaker Change: Or most half of that was one acquisition, the company called Micra.
Vikra, which is a small specialized CRO.
In Med The Devices.
It's actually an Audi S-reposition and we bought that in the third quarter, something in the other, if I remember, and that was almost half of the spend, and we paid almost five times revenue for that.
So obviously it's a big number in terms of the span, but the revenue contribution this year of that acquisition is the Minimus.
Okay, because again, we've been almost five times, we bought that in, you know, that has like been one month of revenue in the quarter.
and that's what it was. So again, very important acquisition as part of our strategy. Thanks for asking the question. By the way, I would remind you the best deal we ever did was the acquisition of the 40% minority.
We did a meet-at-one from our John Xancho with Quest, now Saint-Horlard.
That was the largest deal.
And we've paid $760 million for that. It came with exactly zero revenue because we already consolidated revenue. Right? But it was a great deal, nonetheless.
So again, I hope that helps you to contact to our recommendations strategy. Thank you.
It does.
Your next question comes from the line of Justin Rudd Archabank, your line is open.
Thank you and good morning everyone looking forward to seeing the lab at the Innovation Center in December.
Ari, just sticking with the MNA, I think at the Capitol deployment at the beginning of the year, you guys talked about 2 billion in the deployment, I think when you put together the MNA and the buyback, you're still...
Speaker Change: Tracking below 1 billion. So, you know, assume nothing gets done in the fourth quarter. Would it be fair to assume like sort of like 3 billion of dry powder?
for 2025 and then just...
Lastly related to the comments around pricing pressure, I think earlier you've said it's been mostly concentrated to FSP, are you seeing that spill over it all into FSO?
Okay, well thank you Justin, it's a great question on the capital deployment as you know.
We said no, you know.
Speaker Change: Between $23 billion as a long-term goal, annually spread between acquisitions and shared approaches.
and as you correctly pointed out, so far this year, we've signed the member so far we spent $649 million in our positions and just $200 million on share we purchase.
And you know, frankly that's because we were looking at bigger acquisitions that we were unable to do, either for pricing or other reasons. Acquisitions as you know are binary, you do the hammer, you don't do them. Now, based on what I know today.
I don't think that we're going to spend a lot more on acquisitions before the end of the year. Maybe again I'm speculating between another 50 to 100 million dollars at the most.
Speaker Change: and therefore, as you collect people and tell, they'll just be all of its right power.
Mind tension before the earnings release.
was too massively by share of the 4th quarter and today.
My intention is even to more my figure, but she is.
I can't have the quarter, but I don't count so little things you said on his head here
But I am telling you that we are very excited and we are going to buy a lot of shares. We have 2.2 billion dollars plus.
Speaker Change: Share Bye-Vat Authorization.
and the share price is a screaming buy and that's where we're going to spend our capital. Let's do another question on pricing.
Speaker Change: Ficing stuff across the board has been commercial and RDS obviously.
Speaker Change: Oh, y'all!
Speaker Change: It's not that it's more on FSP than an FSOG
is just that FSB was stronger this year. Remember FSB is perhaps correctly far wrong over here. It's about 15% of revenue. And but it's been increasing in terms of our bookings.
and inching towards 20% right. So eventually it'll be about 20% but again again we might win again other episodes. So I think it'll be always at 15% and 20% and FSP has as you know lower margins.
Speaker Change: So that depresses our, it's a headwind to our mountains because of mixed every time we do more at the speed. pricing is stuff across the board, okay?
Speaker Change: One because, as I mentioned before, this year.
Clients most large-scale companies put us through a sort of a ribbed process.
Invited the every CR-owned of the sun and as I mentioned in my introductory remarks we did.
We're very well there, we're essentially in every single one of these.
Bid processes, we were reselected for existing strategic partnerships and we expanded with half a dozen strategic partners and expanded the scope.
Speaker Change: A vote we are going to be preferred supplies for including especially for Central Lab.
Speaker Change: So we think that the future is very bright.
On on the Earth, again, pricing very tough.
Speaker Change: That's one reason. The other reason is that we have as you know the industry has.
As kind of split between three large siars and then another set of second tier siars who have had, let's say, more trouble in the recent past and who are desperate.
Speaker Change: To win business?
And when you're desperate, the place you go to is price
And so all of that even though they never selected, they end up creating somewhat of a no pricing pressure. And clients of course are going to be delighted to choose them for that purpose. So these are the reasons.
It doesn't look like it's improving, it's going to continue to be tough, but again, we are confident that we will continue to win and do well in the long term. Thank you Justin.
Justin: Thank you, Ari.
Speaker Change: Your next question comes from the line of David with Jeffries, your line is open.
So, hi, thank you for taking my question. Good morning. I wanted to start with just a clarification. I think based on the book to build it, your reporting this morning, you add is about 140 million dollars of new wins.
You know, booking above revenue, your backlogs growing about 500 million is the difference there just FX. So that's clarification. And then, are you thinking about taking...
The timing issues, the cancellations, etc., the pricing pressure that you just commented on. How should we think about your ability to manage cost structure?
and continue to kind of hold margin or deliver margin as you have in the past in this environment. Thank you.
Speaker Change: They've first of all the first observation your math I think is correct. I don't have the numbers in front of me, but based on what I heard, I think you're absolutely on the mark.
with the math on the bookings and the backlog. Your question on the cost management is an excellent one and you probably are inferring from what we said correctly that we have to deal with significant costs.
Speaker Change: had wins for the following reason. These delays, as you can imagine, we had already started up those two mega trials, okay, they were in start-up phase.
and therefore we stood up the resources and infrastructure the teams and everything that's required to perform and deliver on those trials.
Justin: We are interrupted.
Justin: So it's almost like...
But they are going to resume in 25. I think one of them, second quarter and then the rest basically second half and and and romp up in second half.
Now, we are not going to let these resources go and undo what we just did to ramp up the resources. So that already is a cost.
that we have to bear. Now obviously we're going to really approach some of that against some of the other opportunities that has been so long.
Justin: But never the left.
There is no question that we are going to be living here over the next.
Justin: To the Recorder's.
with an extra bucket of costs associated with this.
and these are huge shawlands, okay? And that is going to affect our margins. Now again, we have unfinished our plumbing process. We have a lot of other levers, we are working constantly on costs.
and we, I mean you saw, obviously we haven't yet been affected by this.
Issue so far, but you saw that so far that this year was done pretty well and we've actually in the fourth quarter achieved record margins, I think 24.1% is the highest operating margins.
that we have achieved since the company was created in 16th.
So we've done well, 30 bits of expansion this quarter. But again, in the next two, three quarters, we'll have to see. And we'll share more details.
Justin: on December 10 and certainly on conference with the full year earnings release. But David, you're exactly on the mark. Thank you.
Speaker Change: Great thanks.
Your next question comes from the line of Elizabeth with Evercore I.N.I. Your line is open.
Elizabeth: Hi guys, thanks so much for the question. Maybe one high level question at one number's question. Can you tell me where we are in this sort of strategic partnership? Obviously that's been an area of strength for you guys. But sort of, are we just through this round or we still still beginning this? Is it that not the right way to think about it? And then on the number side, can you have what do you think that interest expense is going to be for 2024 in your updated guidance? Thank you.
Thank you, Elizabeth. Yes, I mean the city partnerships, we did very well this year. We've been working for a long time as we expanded the number of logos that we have before partnerships will.
and so this year and I think it's part of the overall...
Reaction to the IRA and the overall focus on cost management. You know that most large for my company is an massive cost reduction program.
and so they opened up, they really opened all of their vendor relationships. I believe that we are largely true all of that.
Elizabeth: And I think that we are ready to move forward. Most of the large ones essentially have been completed.
Speaker Change: So that's what your first question and some question, guys, you've got to answer. Interest expense, talking about this year a little bit.
Yes, you know, round number 625 or so, give or take around that number which is not terribly different than what we were telling you before.
and do you want to comment on 25 right now or not on that? 25 interest. I mean, it depends on what the Fed and the ECB do with interest rates, but flat-ish for next year is now. We're anticipating, but we'll update as we go along.
Great, thank you very much.
Thank you. Your next question comes from the line of Michael with Leering Partners. Your line is open.
Speaker Change: Morning and thank you for taking the question.
Speaker Change: I know we don't have formal 25 guidance so it might be trending a little lightly here, but relative to R&DF's in the 5% Roth give or take expectation at this point in time.
Speaker Change: One of the conditions have to look like...
Speaker Change: Relator from a macro basis, Kesilation rates, etc., to make sure that number is still feasible. Is that predicated on those two mega trials?
Re-wrapping in the second half and what are the most important puts in takes your focus on that could change versus what the current trend is of general market jobness.
Yeah, I mean look, I wish I had a crystal ball, you know, but I can only tell you what we see now. I believe.
Speaker Change: God.
by the end of the year.
This program reproducivations will come to an end.
We know that because we are in close conversations with our clients and look, that's the business our clients are in is to do research and innovate.
You know, they've been at this for a year and a half.
I think in the middle of last year.
I think this is basically no, what's been re-peritised in cancels. We know what will be cancelled by the end of the year basically.
Now, there could be other trials, there are drug security issues that can always happen, but that's kind of in the normal range of things and we anticipate that. In that new single digit type of high level expectations that we have, as of now.
Speaker Change: 4 25 for on the edge.
That's based on what we know today that has been canceled, the large, you know that we had $350 million program canceled in the quarter.
Speaker Change: That we took in.
We also had in the first quarter last $250 million program cancellation and we know that these two programs may get us as a being delayed and then we factor in everything else. Again, most of the...
and the trials are much smaller than that and we worked on 100s, you know, over 2,000 of them. So it's going to be the normal course of things. These big ones move the needle.
Speaker Change: If you look at R&Ds, go to the Cure, we have 7% in the first quarter, what do we have? The first quarter was ex-COVID, constant currency.
In the school, 8% in school, then we had 6% and 6% in, you know, again, a pass on currency, x-covid basis.
Speaker Change: and then we're going to have 1% in the fourth quarter. So, you know, similar to what I said last year about Taz.
Speaker Change: It might be like a mirror image in 25, with things going the other way. Just because of the cancellations, the shortcoming factor of that, and the delay is the shortcoming factor of that.
So that's our best I can describe what we expect for 25 at this point based on what we know.
Speaker Change: Thank you.
Speaker Change: Thank you, Michael.
There are no further questions at this time, Mr. Joseph, I turn the call back over to you.
Thank you, I'm afraid it. Thank you all for taking the time to join us today and we look forward to speaking for you again at our fourth quarter of 2024 earnings call. The team will be available to the rest of the day to take any follow-up questions you might have. Thank you.
This concludes today's conference call, you may now disconnect.